Millions of Americans are currently taking GLP-1 medications and new research is make the case that resistance training isn’t just complementary to the medication. It’s essential to it.
In Episode 9 of The Research Debrief, hosts Rachel Chonko and Luke Carlson examine what the latest science says about muscle loss during GLP-1 treatment — and why health clubs are uniquely positioned to serve their members who use the medication.
Listen:
What This Episode Covers
This episode breaks down a comprehensive review published in Obesity Review, exploring what the research means for fitness operators and the members they serve.
Key discussion points include:
- Why GLP-1 drugs cause significant muscle loss — and why its not the drugs themselves that are the primary driver.
- How 68-72 weeks of GLP-1 treatment can approximate20 years of age-related muscle loss.
- The role of protein intake and resistance training in preserving lean mass during weight reduction.
- What happens when patients discontinue GLP-1 therapy without an exercise regimen in place.
- How physicians are beginning to look to fitness facilities as essential partners for this care.
Why This Matters for Operators
GLP-1 medications represent one of the most significant public health developments of the past decade — and one of the most consequential opportunities the fitness industry has encountered in years. The research is clear: patients on these drugs who are not engaged in resistance training risk losing substantial amounts of lean muscle mass, undermining the long-term metabolic and health benefits of the weight they’ve lost.
Key implications for operators:
- Targeting GLP-1 users directly through marketing that communicates the critical role of resistance training during and after treatment.
- Pursuing clinical partnerships with primary care physicians and GLP-1 prescribing clinics who are actively seeking exercise programming resources for their patients.
- Training staff to understand the unique needs of members on GLP-1 therapy.
- Positioning resistance training as medical support, not simply a fitness service.
- Preparing for the post-treatment window, when research shows that exercise is the critical variable in preventing weight regain.
GLP-1 drugs are reshaping the healthcare landscape at scale, and the fitness industry has a scientifically validated role to play. Clubs that build programming, messaging and referral relationships around this now will be best positioned to grow their member base and their influence within the healthcare continuum.
Listen or Watch
Audio: Available on SoundCloud, Apple Podcasts and Spotify.
Video: Watch the full episode on YouTube.
Research Referenced in This Episode:
Strategies for Minimizing Muscle Loss During Use of Incretin-Mimetic Drugs for Treatment of Obesity
